China Biologic Products (NASDAQ:CBPO) dropped -5.37% or -6.24 points to trade at $110.03 per share. As per the latest trading data available, the net money flow stood at $12.34 million as the shares received $25.5 million in upticks and gave away $13.16 million in downticks. The final up/down ratio was at 1.94. On a weekly basis, the stock has seen a change of -7.17%.During the course of the session, the shares witnessed a block trade with an up/down ratio of 0. $10.93 million was the inflow in upticks and $0 million was the outflow in downticks. For the block trade, the net money flow was $10.93 million.
Currently the company Insiders own 3.21% of China Biologic Products shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -67.9% . Institutional Investors own 70.06% of China Biologic Products shares. During last six month period, the net percent change held by insiders has seen a change of -84.27%. On the companys insider trading activities, The Securities and Exchange Commission has divulged that Fang Min, director of China Biologic Products, Inc., had unloaded 2,775,000 shares at an average price of $111 in a transaction dated on June 8, 2016. The total value of the transaction was worth $308,025,000.
China Biologic Products (NASDAQ:CBPO) stock ended Monday session in the red zone in a volatile trading. The stock closed down 6.24 points or 5.37% at $110.03 with 532,792 shares getting traded. Post opening the session at $115.59, the shares hit an intraday low of $109.8 and an intraday high of $116.14 and the price was in this range throughout the day. The company has a market cap of $2,926 million and the number of outstanding shares have been calculated to be 26,590,974 shares. The 52-week high of China Biologic Products (NASDAQ:CBPO) is $144.2899 and the 52-week low is $80.6.
Many analysts have stated their opinion on the company shares. Equity analysts at the Brokerage firm Credit Suisse downgrades its rating on China Biologic Products (NASDAQ:CBPO). The rating major has initiated the coverage with neutral rating on the shares. Earlier, the shares were rated a Outperform by the brokerage firm. The rating by the firm was issued on March 1, 2016.
China Biologic Products, Inc. (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. China Biologic has a product portfolio with over 20 different dosage forms of plasma products. The Companys principal products are human albumin and immunoglobulin for intravenous injection (IVIG). China Biologic operates its business through two subsidiaries, namely, Shandong Taibang Biological Products Co. Ltd. and Guizhou Taibang Biological Products Co., Ltd. The Company also holds an interest in Xian Huitian Blood Products Co., Ltd., a plasma products company. Its products include human albumin, human immunoglobulin, IVIG, thymopolypeptides injection, human hepatitis B immunoglobulin, human rabies immunoglobulin, human tetanus immunoglobulin, placenta polypeptide, Factor VIII and human prothrombin complex concentrate (PCC).